Who are High-dose immunoablative therapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-immunoablative-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

High-dose immunoablative therapy — Competitive Intelligence Brief

High-dose immunoablative therapy (High-dose immunoablative therapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoablative therapy with autologous hematopoietic stem cell transplantation. Area: Immunology / Rheumatology.

phase 3 Immunoablative therapy with autologous hematopoietic stem cell transplantation Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

High-dose immunoablative therapy (High-dose immunoablative therapy) — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). High-dose immunoablative therapy uses intensive chemotherapy and/or radiation to eliminate the patient's immune system, followed by autologous hematopoietic stem cell transplantation to reconstitute a new, disease-tolerant immune system.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
High-dose immunoablative therapy TARGET	High-dose immunoablative therapy	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	phase 3	Immunoablative therapy with autologous hematopoietic stem cell transplantation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoablative therapy with autologous hematopoietic stem cell transplantation class)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High-dose immunoablative therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-immunoablative-therapy. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab